If you had been weighing Yatsen on 11 November 2025 and decided against it, the outcome over the next year would have looked very different from what bullish and bearish research argued on paper. For Yatsen shareholders, the loss over the past year was 72.5%, including dividends. With fresh news on weaker net margin and fanfare around 20 research presentations arriving only later, which starting assumption about growth, margins or competition most deserved a tougher challenge at the time?
This theme extends beyond Yatsen. See which of 37 healthcare AI stocks may still merit a closer look.
The Two Yatsen Stories Investors Had To Weigh
The shares cost US$6.71 at the start of the period, and investors in Yatsen were choosing between two sharply different stories built on the same set of facts.
The bullish case saw Asian skincare and premium products opening new markets, with a Fair Value of US$9.18 that reflected an assumed 15.5% annual revenue rise and profit margin moving to 10.8% over three years.
The bearish view pinned Fair Value at US$3.4, based on concerns that Chinese macro pressure and rising regulatory costs would squeeze margins even if revenue grew 18.4% a year.
What The Yatsen Evidence Actually Tested
The clearest new fact was Yatsen unveiling 20 research presentations at the IFSCC Congress, which supported the emphasis on R&D and product science. The results pointed in a different direction. Revenue moved from CNY1,086.732m in Q2 2025 to CNY1,142.18m in Q2 2026, while net income remained in loss and net margin declined from a 1.6% loss to an 8.0% loss. The evidence had mixed implications.
The key assumption in this case was that profit quality would catch up with the product narrative. When you look at another stock, track whether net margin and absolute profit are moving toward the forecast path that supported the original thesis.
What A Buyer Of Yatsen Is Really Paying For Today
Yatsen now trades at US$1.92, after a 72.5% loss over the past year from US$6.71. The bullish analyst narrative on Simply Wall St sees fair value above that level, based on the idea that skincare and science led branding could eventually support stronger profitability.
Anyone paying today is effectively judging whether Yatsen can turn its R&D platform and channel mix shift into sustained profit with tighter marketing spend.
"The main thing that has to go right is that Yatsen Holding turns its R&D platform and channel mix shift into sustainable profitability, keeping selling and marketing costs in check while competition and digital traffic costs remain intense."
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for
Looking Beyond Yatsen’s Shelves
Yatsen leans on product science and brand stories. You might also consider who scales similar ideas across everyday essentials.
Instead of colour cosmetics, think haircare, soap and basic skincare in most bathrooms. That different mix still rewards trusted labels and repeat habits.
One large group is reshaping around beauty, personal care and home products, with ice cream and some foods pushed aside.
It is pursuing premium, science backed ranges, heavier brand spending and AI supported research to refine pricing power and efficiency.
If that remodel works, potential gains may come from steadier volumes and margins tied to routine purchases rather than fashion cycles.
That argument has a Narrative and a number behind it. → See the company one Narrative values 22% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com